Cel-sci presents head & neck cancer data at iddst annual congress in budapest: risk of death cut in half for patients treated with multikine in the target population

Vienna, va.--(business wire)---- $cvm #multikine--cel-sci corporation (nyse american: cvm) today announced the company's chief scientific officer, dr. eyal talor, delivered a presentation titled “neoadjuvant immunotherapy for head and neck cancer: low tumor pd-l1 expression - it-matters – rct” at the international drug discovery science & technology (iddst) 20th annual congress in budapest, hungary on tuesday, june 18, 2024. dr. talor presented during the cancers/tumors session which he chaired along with dr.
SCI Ratings Summary
SCI Quant Ranking